Warning over high doses of muscle relaxant in renal patients
Baclofen trebles the risk of encephalopathy in chronic kidney disease, study shows
Doctors are being warned about increased risk of encephalopathy with higher doses of baclofen in patients with chronic kidney disease.
Patients taking the muscle relaxant t doses higher than 20mg daily face a 3.5-fold raised risk of hospitalisation with encephalopathy compared with those on less than 20mg daily, a study shows.
The Canadian authors say their findings reveal “quite clearly the potential harm of this drug” in patients with the condition.
At least 30 international case reports have linked the muscle relaxant baclofen to encephalopathy soon after initiation in patients with chronic kidney disease, said the researchers from London, Ontario.
